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Abstract
Purpose The hypothesis of this clinical study was to
determine whether glucocorticoid use and immobility were
associated with in-hospital nutritional risk.
Methods One hundred and one patients consecutively
admitted to the medical wards were enrolled. Current
medical conditions, symptoms, medical history, eating and
drinking habits, diagnosis, laboratory findings, medica-
tions, and anthropometrics were recorded. The Nutrition
Risk Score 2002 (NRS-2002) was used as a screening
instrument to identify nutritional risk.
Results The results confirmed that glucocorticoid use and
immobility are independently associated with nutritional
risk determined by the NRS-2002. Constipation could be
determined as an additional cofactor independently asso-
ciated with nutritional risk.
Conclusions Glucocorticoid treatment, immobility, and
constipation are associated with nutritional risk in a mixed
hospitalized population. The presence of long-time
glucocorticoid use, immobility, or constipation should alert
the clinician to check for nutritional status, which is an
important factor in mortality and morbidity.
Keywords Malnutrition  Nutritional risk screening 
Glucocorticoid treatment  Immobility  Constipation
Introduction
Protein-energy malnutrition (PEM) is an independent risk
factor for increased number of complications, increased
morbidity and mortality, increased length of hospital stay,
and increased costs [1–3] and has a prevalence of between
30 and 50% in hospitalized patients [4–6]. Malnutrition and
illness influence each other: on the one hand, the illness
itself can worsen the nutritional state, and on the other
hand, malnutrition can negatively affect the course of the
illness. As malnutrition is a largely treatable co-morbidity,
rapid and simple identification and effective management
of this condition are essential [7].
For hospitalized patients, the NRS-2002, introduced by
Kondrup et al., is a valid and reliable indicator of patients
at nutritional risk [8]. Nutritional risk includes character-
istics that are associated with an increased likelihood of
poor nutritional status. The purpose of nutritional screening
is to predict the probability of a better or worse outcome
due to nutritional factors and whether nutritional treatment
is likely to influence this. Our group has shown that
patients at nutritional risk undergoing elective colorectal
surgery have higher in-hospital mortality and morbidity
[9]. However, mechanisms and cofactors involved and
related to malnutrition have not been identified.
Sarcopenia is defined as age- or disease-related muscle
loss, and nutritional risk is very well known in geriatric
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patients. A study from the group of Sieber and co-workers
presented a model for the connections between frailty,
sarcopenia, and risk of malnutrition in geriatric patients
[10]. The authors described a vicious cycle involving sar-
copenia and immobilization: sarcopenia leads to neuro-
muscular impairment, resulting in falls and fractures. The
consequence of fractures is immobilization, which ulti-
mately induces sarcopenia.
PEM is believed to cause hypercortisolemia [11].
Cortisol’s effects are mediated through the glucocorticoid
receptor, which binds the hormone in the cytosol, translo-
cates to the nucleus, and promotes gene transcription [12].
Lunn and co-workers found a dose-dependent increase in
the plasma concentration of cortisol in relation to muscle
wasting in children: the more wasted the children’s mus-
cles, the higher the cortisol levels observed [13]. In rat
experiments, injection of glucocorticoids led to a slow,
continuous decrease in body weight throughout the
experiment. Analysis of the weight loss showed that glu-
cocorticoid-treated animals lost more muscle mass than
controls. Interestingly, the glucocorticoid-treated rats did
not have any change in food intake compared to controls
[14]. Glucocorticoids not only stimulate proteolysis but
also inhibit protein synthesis and the transport of amino
acids into muscle, and these coordinated actions promote
the mobilization of amino acids used for glucogenesis [15].
Hypercortisolism has been implicated as an important
contributing factor in muscle wasting: in vitro experiments
have shown induction of muscle catabolism by glucocor-
ticoids [16]. An interesting model for glucocorticoid excess
in humans is Cushing’s disease. Weakness and proximal
muscle wasting are common in Cushing’s syndrome and
are induced by the catabolic effects of excess glucocorti-
coids on skeletal muscle. The catabolic effects of gluco-
corticoids are amplified by physical inactivity [17].
Nevertheless, other researchers hypothesize that pure glu-
cocorticoid excess does not cause weight loss but rather
weight gain and visceral obesity and that normalization of
glucocorticoid excess in Cushing’s syndrome is associated
with significant loss of body weight, but muscle mass
remained on a constant low level [18]. In addition, exten-
ded use of glucocorticoids in patients with inflammatory
bowel disease is associated with mortality in contrast to the
use of other immunosuppressants [19].
A period of confinement in bed often precedes death
[20]. Although immobility is a key aspect of sarcopenia,
we found few reports on this issue in the medical literature.
This is surprising, because hospital patients are frequently
bedridden. In addition, constipation has been associated
with a bedridden state in geriatric patients [21, 22].
Our hypothesis was that glucocorticoid use and immo-
bility are associated with in-hospital nutritional risk and
that constipation can act as a modifier in this context.
Materials and methods
Study design
In a cross-sectional study of patients hospitalized on the
general internal medicine wards of the Bern University
Hospital, we investigated possible factors for nutritional
risk as defined by the NRS-2002.
Selection of participants, recruitment, and approval
Over four consecutive weeks, all patients admitted to the
wards were invited to participate in the study. Patients were
considered eligible if they were 18 years or older and were
willing and able to give written informed consent. Exclu-
sion criteria were patients with psychological disorders,
dementia, poor knowledge of the study language, or
symptomatic heart, renal, or liver failure. All participants
provided written informed consent before enrollment, and
the study protocol was approved by the ethics committee of
the University of Bern.
Data and measurements
A specialist in clinical nutrition (trained physician)
screened the participants for nutritional risk using the
NRS-2002 [23] within 24 h after admission. Nutritional
risk was evaluated by two components—nutritional state
and severity of disease—each with a value ranging from 0
to 3 points. The score of severity of disease reflects
increased nutritional requirements due to stress metabo-
lism. Nutritional state was based on three variables: body
mass index (BMI), recent weight loss, and dietary intake
during the last week before admission. The most com-
promised of the three variables is used for the NRS-2002
to categorize the patient. Dietary intake, as a semi-quan-
titative scale, was included and was given the same
weight as the other variables, despite the fact that few
previous studies have used dietary history as part of the
initial characterization of the patients. Classification of a
patient as at risk using dietary history alone will only
occur with a C1 week’s history of an intake equal to
0–25% of a patient’s estimated nutritional requirements,
and such a history can probably be obtained with a suf-
ficient degree of certainty in most cases. It has been
shown that nurses’ dietary recording in quartiles agrees
reasonably well with the dietician’s recording [24], and it
may be assumed that a recent dietary history also will be
reasonably reliable.
The score for nutritional status was added to the score
for severity of disease to give a total score, which could
range from 0 to 6. For older participants (C70 years), a
value of 1 was added to the total score to correct for age.
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Participants with a total score C3 were considered nutri-
tionally at risk.
Sex, age, current medical conditions, current symptoms,
unintentional weight loss, eating and drinking habits, living
and social situation, daily activity, medications and illicit
drug use, smoking, alcohol intake, and primary diagnosis
were recorded. A complete physical examination was
performed, and blood pressure, heart rate, and body tem-
perature were reported. Anthropometric data included
weight (nearest 0.1 kg), height (nearest 0.01 m), BMI
(calculated as weight/height2), skin-fold thickness (triceps,
biceps, back, abdomen, and thigh; nearest 1 mm), and
upper arm circumference (nearest 0.1 cm). All skin-fold
thickness measurements were performed three times
(serially) by one examiner with a Lange caliper, using the
mean value of the three measurements. Routine laboratory
tests were performed, including measurement of albumin,
prealbumin, and transferrin.
After values were obtained for the triceps skin-fold
(= TSF in mm) and the mid-arm circumference (= MAC in
cm), the mid-arm muscle area (= MAMA in cm2) was
calculated using the corrected formula described by
Heymsfield et al. [25]:
For men: [(MAC - p 9 TSF)2: 4p]-10
For women: [(MAC - p 9 TSF)2: 4p]-6.5
A bioimpedance analysis (BIA) was performed for
every patient using the Bioimpedance Analyzer Model
STA, Soft Tissue-analyzer (Akern Bioresearch, Florence,
Italy) with an operating frequency of 50 kHz at 800 mA
and standard electrode locations on the right hand and foot.
Phase angle was taken as one measurement, incorporating
information on reactance and impedance. Whole-body BIA
measurements were taken with the subject in a supine
position on a non-conducting surface, with the arms
slightly abducted from the trunk and the legs slightly
separated, as previously described [26]. All patients were
measured by the same two members of the hospital staff.
The software used was BC3GERM version 1.4 (Akern/
Fresenius, Bad Homburg, Germany). In each patient, we
measured the fat-free mass, the body fat, the body cell
mass, the total body water, the extracellular water, and the
intracellular water. For body cell mass calculation, the
formula of Roza et al. was used [27]. For lean body mass
calculation, the formula of Moore et al. was used [28].
Statistical analysis
Means and proportions of variables were calculated for
participant characteristics. Bivariate analysis was used to
compare prevalence of glucocorticoid treatment, immobil-
ity, and constipation in patients at nutritional risk (NRS-
2002 C 3) and not at risk (NRS-2002 \ 3). In a first step,
continuous data were analyzed by QQplots to test for normal
distribution of the sample. If data were normally distributed,
a parametric two-sided test such as Student’s t-test was used;
if data distribution was abnormal, Wilcoxon signed-rank
tests were used. For binary data, chi-square tests were used.
To reduce the possibility of confounders, the effects and
their magnitude were analyzed in a multiple logistic
regression model in stepwise fashion. Nutritional risk
defined by an NRS-2002 score C 3 was used as dependent
variable. To test whether a factor was a possible confounder
(i.e., age, height, lean body mass, transferrin, and diagnosis
of malignancy) or had an importance in association with
nutritional risk, likelihood ratio tests were performed
between the different logistic regression models. To test for
potential interactions between factors of the logistic
regression models, we used the respective interaction terms
of our statistical software. In a possible case of collinearity,
Mantel–Haenszel analysis was used and statistical signifi-
cance of the interaction was then determined using the
Breslow–Day test of homogeneity.
Weight and BMI were not tested for possible colinear-
ity, because by definition, the NRS-2002 includes weight
loss. A p value (two-sided) \0.05 was considered as sta-
tistically significant. Data analysis was performed with
STATA for Windows, version 6.0 (StataCorp LP, College
Station, Texas, USA).
Results
One hundred and fifty-one patients were admitted to the
general medical wards during January 2004, 101 of whom
were eligible for and agreed to participate in the study.
Participant characteristics are shown in Table 1, divided
into patients at nutritional risk (NRS-2002 C 3) or not at
risk (NRS-2002\ 3). Participants who were excluded were
not significantly different from the included participants
with regard to age, gender, or clinical and laboratory
findings; thus, our study collective is representative of the
patients on the general medical wards of our university
hospital (data not shown).
To check whether characteristics of patients at nutri-
tional risk have changed since 2004, data from our quality
control database of February 2008 were taken to compare
prevalence of patients at nutritional risk in our department
of internal medicine [29]. The prevalence was 53% in 2008
and was not significantly different from the data set pre-
sented here. Nutritional risk, defined by an NRS-2002 total
score C3, was identified in 48% of participants.
Sixteen out of 101 patients were on glucocorticoid
treatment for ulcerous colitis, chronic obstructive pul-
monary disease, or malignancy. The groups in 2004 and
2008 did not significantly differ in age, polypharmacy, or
Eur J Nutr (2011) 50:665–671 667
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the number of diagnoses. In 2004, the prevalence of glu-
cocorticoid treatment (daily prednisone use [7.5 mg) was
25% in patients at nutritional risk, compared to 8% in
patients not at risk (p = 0.02). Similarly, 46% of the
patients at risk were immobile, compared to 27% of the
patients not at risk, a statistically significant difference
(p = 0.04). Finally, 52% of the patients at nutritional risk
had constipation, compared to only 34% of the population
not at risk (p = 0.07), a difference of nearly 20%. These
results are shown in Fig. 1.
Patients at risk with NRS-2002 C 3 showed a reduced
MAMA of 40.7 ± 1.5 cm2, versus 53.1 ± 2.1 cm2 in
patients not at risk (p \ 0.001). We included possible
confounding factors in the model such as malignancy, age,
height, and lean body mass. None of these factors were
significant or had an influence in the logistic statistical
multivariate model (Table 2). In the multivariate model,
glucocorticoid treatment was strongly associated with a
state of nutritional risk, OR 8.2 (95% CI 1.7–39.2).
Immobility (OR 3.2 [95% CI 1.2–8.6]) and constipation
(OR 2.3 [95% CI 0.9–5.8]) were associated with nutritional
risk, whereas MAMA and female sex were inversely
associated with nutritional risk, respectively. In general, no
interaction was found between the factors in the multi-
variate model. However, a possible interaction of consti-
pation in patients under glucocorticoid treatment associated
with nutritional risk could not be completely excluded.
Mantel–Haenszel analysis and Breslow test showed a
p value of 0.18.
Discussion
Sarcopenia is a term that describes the connection between
muscle loss, risk of malnutrition, and immobility, which
again induces neuromuscular impairment. Whitehead and
Lunn [11] first proposed an association between hyper-
cortisolism and malnutrition. The aim of our study was to
test the hypothesis that glucocorticoid use and immobility
are associated with nutritional risk. Because data exist that
Table 1 Bivariate analysis of
factors associated with
nutritional risk
SD standard deviation, NRS-
2002 \ 3 not at nutritional risk,
NRS-2002 C 3 at nutritional
risk, n number of patients
Asterisks indicate that p values
are presented in two decimal
places
Characteristics (mean ± SD) NRS-2002 \ 3 NRS-2002 C 3 p
Age (years) 55.4 ± 17.5 64.1 ± 17.1 0.01
Sex (total, counts) 48 53 0.21
Males 32 23
Females 21 25
Height (cm) 170.5 ± 10.8 164.4 ± 9.3 0.01
Weight (kg) 74.7 ± 16.8 60.3 ± 14.8 0.01
Body mass index (kg/m2) 25.7 ± 5.4 22.2 ± 4.5 0.01
Triceps skin-fold (mm) 11.1 ± 6.2 9.1 ± 5.1 0.09
Mid-arm circumference (cm) 25.6 ± 3.5 22.5 ± 2.8 0.01
Mid-arm muscle area (cm2) (total)
Males 47.4 ± 14.1 36.3 ± 8.6 0.01
Females 31.1 ± 16.3 26.3 ± 5.9 0.18
Lean body mass (%) 53.1 ± 10.7 43.8 ± 10.0 0.01
Fat mass (%) 21.7 ± 11.3 16.6 ± 8.1 0.01
Albumin (g/L) 36.7 ± 7.1 31.6 ± 5.9 0.01
Prealbumin (g/L) 0.21 ± 0.08 0.20 ± 0.09 0.70
Transferrin (g/L) 1.97 ± 0.47 1.73 ± 0.40 0.01
Main diagnosis group (n) NRS-2002 \ 3 (%) NRS-2002 C 3 (%)
Cardiovascular disease (n = 39) 39.6 37.5* 0.83
Thoracopulmonal disease (n = 34) 32.1 35.4* 0.72
Abdominal disease (n = 19) 18.9 18.8* 0.99
Malignancy (n = 32) 18.9 45.8** 0.01
Endocrinological disease (n = 22) 14.5 18.8* 0.48
Neurological disease (n = 21) 28.3 12.5* 0.05
Skeletal disease (n = 6) 5.6 6.2* 0.90
Glucocorticoids 7.5 25 0.02
Constipation 34.0 52.1 0.07
Immobility 26.6 45.8 0.04
668 Eur J Nutr (2011) 50:665–671
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show an association between physical activity and consti-
pation, we additionally investigated whether constipation
could be a cofactor associated with malnutrition.
The results of our study confirmed that glucocorticoid
use and immobility are independently associated with a
risk of malnutrition determined by the NRS-2002. To our
surprise, constipation seems to have an association with
nutritional risk. In addition, we found, not surprisingly, that
middle-arm muscle area was reduced in patients at nutri-
tional risk. Chronic glucocorticoid use may result in
reduction in muscle mass, an effect demonstrated by a
decrease in middle-arm muscle mass as a result of gluco-
corticoid-induced catabolism. The reduced muscle mass
leads to reduced mobility and a higher risk of falls, which
ultimately confines a patient to his bed. To be bedridden is
a further risk factor for catabolism, which, in addition to
glucocorticoid treatment, is represented by a significant
odds ratio in association with an NRS-2002 C 3. However,
because the design of this study is cross-sectional, it is not
possible to determine whether glucocorticoids themselves
lead to a higher risk of malnutrition. Several points favor
the hypothesis that glucocorticoid treatment leads to
nutritional risk and muscle wasting.
Glucocorticoids
Glucocorticoids have a proteolytic effect, which in and of
itself can contribute to nutritional risk. In inflammatory
bowel disease, there are hints that the risk of malnutrition
may be related to an accumulated glucocorticoid dose.
Bernal et al. [30] found that the clinical failure to respond
to systemic glucocorticoids in active colitis was associated
with the presence of nutritional risk. Another study from
Geerling et al. [31] showed a variety of nutritional and
functional deficiencies in patients with long-standing
Crohn’s disease in remission, especially those with a high
lifetime prednisone dose. Furthermore, it is well known
that Cushing’s syndrome is accompanied by muscular
atrophy of the proximal extremities. These examples from
the literature on glucocorticoids support our hypothesis
drawn from the multiple logistic regression equation pre-
sented in Table 2.
Immobility
Another factor associated with high nutritional risk in our
study was immobility. Immobile patients were defined as
patients confined to their bed due to illness and unable to
get up for use of the toilet. It is not surprising that
immobility is a strong contributor to nutritional risk. Forty-
five percent of our patients with nutritional risk were on
bed rest, compared to 25% of the population not at risk. In
the bivariate analysis, immobility alone is statistically
significant, with a p value of 0.04 for patients with an NRS-
2002 C 3. When the factor ‘‘immobility’’ was analyzed
along with the factor ‘‘glucocorticoid treatment’’ in a
multivariate model, the association of glucocorticoid use
and nutritional risk did not change in a relevant fashion
[OR 4.59 (95% CI: 1.31–16.05, with immobility) from OR
4.54 (95% CI: 1.32–15.66, without immobility)]. Thus,
immobility is an independent predictor of nutritional risk
and has no interactive effect on the association between
glucocorticoid use and nutritional risk.
This statistical effect was previously observed by
Ferrando and co-workers in an experimental study with
human volunteers [17]: they found that bed rest had an
amplifying effect on the catabolic response of skeletal
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Fig. 1 Univariate analysis demonstrates a predominance of steroid
treatment, immobility, and constipation in patients at nutritional risk
versus patients not at risk (prevalence of steroid treatment: 25%
versus 8%; prevalence of immobility: 46% versus 26%; prevalence of
constipation: 52% versus 34%)
Table 2 Odds ratios (OR) and 95% confidence intervals (CI) of the
factors obtained by multiple logistic regression analysis for all
patients at nutritional risk (n = 100, NRS-2002 C 3; 1 observation
omitted due to missing values)
OR SE z value p value 95% CI
Glucocorticoid use 8.16 6.54 2.62 0.0096 1.70–39.24
Immobility 3.23 1.64 2.312 0.021 1.194–8.76
Constipation 2.27 1.08 1.73 0.084 0.90–5.79
Mid-arm muscle area 0.92 0.26 -2.85 0.004 0.87–0.97
Gender 0.71 0.44 -0.55 0.580 0.21–2.39
Units of measurement yes/no, Immobility yes/no, Constipation yes/
no, Mid-arm muscle are in cm2, Gender female/male
The model was adjusted for age (p = 0.48), height (p = 0.37), and
lean body mass (p = 0.06)
SD standard deviation, LR Chi2 31.65, Prob [ Chi2 0.000, Pseudo-R2
0.229, Log likelihood -53.41
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muscle to an infusion of hydrocortisone succinate, deter-
mined by phenylalanine kinetics. The authors demonstrated
experimentally that absence of muscular activity sensitizes
skeletal muscle to the catabolic effects of cortisol. These
findings are reflected in the data from our study as well.
Constipation
Of the initially proposed gastrointestinal symptoms evalu-
ated, only constipation was associated with an NRS-2002
C 3; nausea and diarrhea did not show any association.
Constipation was defined as having a bowel movement
fewer than three times per week and stools that were
usually hard, dry, small in size, and difficult to eliminate. In
the bivariate analysis, we could only find a trend and not a
statistically significant association between constipation
and risk of malnutrition (p = 0.07). Because the preva-
lence of constipation in the population at nutritional risk
was over 30% and clearly above the prevalence in the
general population (15%), we included constipation in the
multivariate model to avoid a type II error. In the model
that included glucocorticoid use, immobility, and consti-
pation alone (data not shown), constipation was an inde-
pendent statistically significant factor (p = 0.044), with an
OR of 2.41. After inclusion of middle-arm muscle area in
the model, constipation was identified as an independent
risk factor for nutritional risk with a tendency to be sta-
tistically significant. In addition, a possible interaction of
constipation with glucocorticoid use and to be at risk of
malnutrition could not be excluded by our data, a possible
reason for that could be lack of study power. We suggest
that muscle atrophy affects not only skeletal muscle fibers
but also smooth muscle fibers. This might be an explana-
tion for slower gastrointestinal transit.
Mid-arm muscle area
Not surprisingly, the mean MAMA was reduced by more
than 20% in the population at nutritional risk compared to
the patients not at risk. This factor was negatively corre-
lated with the nutritional risk in the multivariate model
(Table 2).
The 95% CI for age of our study population was
56–63 years, with a range of 18–89 years. Thus, according
to our data, our model for risk of malnutrition and therefore
frailty and sarcopenia can be applied not only to a geriatric
population but also to a much younger population.
Conclusion
Glucocorticoid treatment, immobility, and constipation are
associated with nutritional risk as defined by the NRS-2002
in a mixed hospitalized population. The presence of con-
stipation, long-time glucocorticoid use, or immobility
should alert the clinician to check for nutritional status,
which is an important factor in mortality and morbidity.
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